Assessment of PI3K/mTOR/AKT Pathway Elements to Serve as Biomarkers and Therapeutic Targets in Penile Cancer by Thomas, Anita et al.
Kent Academic Repository
Full text document (pdf)
Copyright & reuse
Content in the Kent Academic Repository is made available for research purposes. Unless otherwise stated all
content is protected by copyright and in the absence of an open licence (eg Creative Commons), permissions 
for further reuse of content should be sought from the publisher, author or other copyright holder. 
Versions of research
The version in the Kent Academic Repository may differ from the final published version. 
Users are advised to check http://kar.kent.ac.uk for the status of the paper. Users should always cite the 
published version of record.
Enquiries
For any further enquiries regarding the licence status of this document, please contact: 
researchsupport@kent.ac.uk
If you believe this document infringes copyright then please contact the KAR admin team with the take-down 
information provided at http://kar.kent.ac.uk/contact.html
Citation for published version
Thomas, Anita, Reetz, Sascha, Stenzel, Philipp, Tagscherer, Katrin, Roth, Wilfried, Schindeldecker,
Mario, Michaelis, Martin, Rothweiler, Florian, Cinatl, Jindrich, Cinatl, Jaroslav and others  (2021)
Assessment of PI3K/mTOR/AKT Pathway Elements to Serve as Biomarkers and Therapeutic
Targets in Penile Cancer.   Cancers, 13  (10).   p. 2323.  ISSN 2072-6694.
DOI
https://doi.org/10.3390/cancers13102323






Assessment of PI3K/mTOR/AKT Pathway Elements to Serve as
Biomarkers and Therapeutic Targets in Penile Cancer
Anita Thomas 1, Sascha Reetz 1, Philipp Stenzel 2 , Katrin Tagscherer 2, Wilfried Roth 2, Mario Schindeldecker 2 ,
Martin Michaelis 3 , Florian Rothweiler 4, Jindrich Cinatl Jr. 4, Jaroslav Cinatl 4, Robert Dotzauer 1 ,
Olesya Vakhrusheva 1, Maarten Albersen 5, Stephan Macher-Goeppinger 1, Axel Haferkamp 1, Eva Juengel 1,
Andreas Neisius 1,6,† and Igor Tsaur 1,*,†


Citation: Thomas, A.; Reetz, S.;
Stenzel, P.; Tagscherer, K.; Roth, W.;
Schindeldecker, M.; Michaelis, M.;
Rothweiler, F.; Cinatl, J., Jr.; Cinatl, J.;
et al. Assessment of
PI3K/mTOR/AKT Pathway
Elements to Serve as Biomarkers and
Therapeutic Targets in Penile Cancer.
Cancers 2021, 13, 2323. https://
doi.org/10.3390/cancers13102323
Academic Editors: Paola Ferrari and
Andrea Nicolini
Received: 7 April 2021
Accepted: 7 May 2021
Published: 12 May 2021
Publisher’s Note: MDPI stays neutral
with regard to jurisdictional claims in
published maps and institutional affil-
iations.
Copyright: © 2021 by the authors.
Licensee MDPI, Basel, Switzerland.
This article is an open access article
distributed under the terms and
conditions of the Creative Commons
Attribution (CC BY) license (https://
creativecommons.org/licenses/by/
4.0/).
1 Department of Urology and Pediatric Urology, University Medicine Mainz, 55122 Mainz, Germany;
anita.thomas@unimedizin-mainz.de (A.T.); sascha.reetz@unimedizin-mainz.de (S.R.);
robert.dotzauer@unimedizin-mainz.de (R.D.); olesya.vakhrusheva@unimedizin-mainz.de (O.V.);
sgoeppinger@gmail.com (S.M.-G.); axel.haferkamp@unimedizin-mainz.de (A.H.);
eva.juengel@unimedizin-mainz.de (E.J.); a.neisius@bk-trier.de (A.N.)
2 Department of Pathology, University Medicine Mainz, 55122 Mainz, Germany;
philipp.stenzel@unimedizin-mainz.de (P.S.); katrin.tagscherer@unimedizin-mainz.de (K.T.);
wilfried.roth@unimedizin-mainz.de (W.R.); mario.schindeldecker@unimedizin-mainz.de (M.S.)
3 Industrial Biotechnology Centre and School of Biosciences, University of Kent, Canterbury CT2 7NJ, UK;
M.Michaelis@kent.ac.uk
4 Institute of Medical Virology, Goethe-University, 60596 Frankfurt am Main, Germany;
f.rothweiler@kinderkrebsstiftung-frankfurt.de (F.R.); cinatl@em.uni-frankfurt.de (J.C.J.);
ja.cinatl@kinderkrebsstiftung-frankfurt.de (J.C.)
5 Department of Urology, University Hospitals Leuven, 3000 Leuven, Belgium; maarten.albersen@uzleuven.be
6 Department of Urology and Pediatric Urology, Krankenhaus der Barmherzigen Brüder Trier,
54292 Trier, Germany
* Correspondence: igor.tsaur@unimedizin-mainz.de; Tel.: +49-6131-172312
† These authors contributed equally.
Simple Summary: Penile cancer is a rare but aggressive malignancy characterized by rapid tumor
growth as well as prompt metastasis in groin lymphatics. While localized diseases can be successfully
cured by surgery in most cases, no truly effective treatment options have been established for
metastatic diseases as of yet. In the current investigation, we assessed the value of selected members
of the PI3K/mTOR/AKT pathway to serve as tumor markers or therapeutic targets for this disease.
Higher expression of AKT was significantly more prevalent in high-grade tumors and independently
predictive of the worse survival parameters, while increased expression of pmTOR was associated
with an inferior prognosis as well. Treatment with the pan-AKT inhibitor capivasertib in PeCa cell
lines induced significant reduction of cell viability and movement capacity. These findings might aid
in the understanding of the molecular tumor background as well as development of novel treatment
options for advanced penile cancer.
Abstract: The PI3K/mTOR/AKT pathway might represent an intriguing option for treatment of
penile cancer (PeCa). We aimed to assess whether members of this pathway might serve as biomarkers
and targets for systemic therapy. Tissue of primary cancer from treatment-naïve PeCa patients was
used for tissue microarray analysis. Immunohistochemical staining was performed with antibodies
against AKT, pAKT, mTOR, pmTOR, pS6, pPRAS, p4EBP1, S6K1 and pp70S6K. Protein expression
was correlated with clinicopathological characteristics as well as overall survival (OS), disease-specific
survival (DSS), recurrence-free survival (RFS) and metastasis-free survival (MFS). AKT inhibition was
tested in two primarily established, treatment-naïve PeCa cell lines by treatment with capivasertib
and analysis of cell viability and chemotaxis. A total of 76 patients surgically treated for invasive PeCa
were included. Higher expression of AKT was significantly more prevalent in high-grade tumors and
predictive of DSS and OS in the Kaplan–Meier analysis, and an independent predictor of worse OS
and DSS in the multivariate regression analysis. Treatment with pan-AKT inhibitor capivasertib in
PeCa cell lines induced a significant downregulation of both total AKT and pAKT as well as decreased
cell viability and chemotaxis. Selected protein candidates of the mTOR/AKT signaling pathway
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demonstrate association with histological and survival parameters of PeCa patients, whereas AKT
appears to be the most promising one.
Keywords: penile cancer; AKT; mTOR; cell lines; biomarker; targeted therapy
1. Introduction
Penile cancer (PeCa) is a rare but aggressive malignancy characterized by rapid
tumor growth as well as prompt lymphatic metastasis [1]. In a localized disease, cure can
be achieved in most patients. However, despite the increasing knowledge of molecular
carcinogenesis and utilization of different systemic agents in clinical trials in the last decade,
the prognosis still remains extremely poor for metastatic PeCa [2]. After failing the first-
line, cisplatin-based chemotherapy, providing a progression-free survival of 20 weeks
and response rate of 30%, overall survival falls short of 6 months [3]. Further scientific
efforts targeted at profound deciphering of the molecular driver machinery in PeCa are
ultimately warranted in order to pave the way for the development of more effective and
individualized systemic protocols.
In this context, the preliminary data suggest that the PI3K/mTOR/AKT pathway
might represent an intriguing option for the targeted treatment of PeCa. Phosphoinositide 3
kinase (PI3K) and its downstream mediator serine/threonine kinase AKT and mechanistic
target of rapamycin (mTOR) constitute the core components of this signaling cascade,
critically regulating such essential cellular processes as cell cycle progression and cell
survival [4]. Importantly, activation of PI3K can be initiated by several mechanisms
involving receptor tyrosine kinases such as the epidermal growth factor receptor (EGFR)
and insulin-like growth factor-1 receptor (IGF-1R), cell adhesion molecules such as integrins,
G-protein coupling receptors (GPCR) or oncogenes, such as Ras [5]. Upon activation, PI3K
phosphorylates phosphatidylinositol-4,5-bisphosphate (PIP2) to phosphatidylinositol-3,4,5-
trisphosphate (PIP3), which in turn activates AKT. At the same time, negative regulation of
AKT can be achieved by dephosphorylation of PIP3 to PIP2 by the phosphatase and tensin
homolog (PTEN) [4].
Alterations of proteins involved in PI3K/AKT/mTOR signaling are known to be in-
volved in tumorigenesis of a plethora of malignancies. Activating mutations in the PIK3CA
gene, which encodes the p110 catalytic subunit of PI3K, have been described in 36% of uterine
endometrioid, 32% of colorectal and 25%–40% of breast cancer, resulting in the increased
expression rate of total and phosphorylated AKT (pAKT) [6–10]. Moreover, overexpressed
pAKT was detected in endometrial, prostate as well as pancreatic cancer [11,12]. For PeCa,
scant evidence exists on the diagnostic and prognostic value of the molecular elements of the
PI3K/AKT/mTOR signaling pathway thus far. In this study, we aimed at assessing the key
players of this pathway for their potential to serve as tissue tumor markers and potential
targets for systemic therapy.
2. Materials and Methods
2.1. Study Patients
A tissue microarray (TMA) consisting of PeCa tissue was used for this study. Tissue
samples were provided by the tissue bank of the University Medical Center Mainz in
accordance with the regulations of the tissue bank. All PeCa cases were collected from
surgically treated patients with invasive PeCa from 1980 to 2018 at our institution and
were confirmed blinded to the patient outcomes by experienced genitourinary pathologists.
Disease management adhered to the currently valid European Association of Urology
(EAU) Guidelines on Penile Cancer. All tumors were graded and staged according to
the currently valid World Health Organization (WHO) and TNM classifications. A panel
of clinical and histopathological parameters, including age at diagnosis, comorbidities,
primary tumor surgery, tumor grade, pathologic T-stage, N-stage, status of infection with
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human papillomavirus (HPV), disease recurrence and its site, subsequent therapy and
cause of death were collected for correlation with marker expression. Recurrence was
classified as local (recurrent tumor on the penis), regional (recurrent disease in the inguinal
or pelvic lymph nodes), or distant (remote metastasis), in adherence with a commonly
used classification [13]. In the case of regional and distant recurrence in the same patient, it
was classified as distant due to higher prognostic relevance. The follow-up protocol was
defined as time from initial surgery until the last follow-up or death.
All patients with available formalin-fixed paraffin-embedded PeCA tissue samples
were included in the TMA constructed as previously described [14]. First, representative
tissue blocks were selected as donor blocks. From each donor block, sections were prepared
and stained with H&E. Subsequently, from each PeCa tissue sample, a morphologically
representative region was chosen. Two cylindrical core tissue specimens per tumor block
(diameter, 1 mm) from these regions were punched and arrayed into the recipient paraffin
block by usage of a semiautomatic system Tissue Arrayer MTA-1 (AlphaMetrix, Chicago,
IL, USA).
2.2. Immunohistochemical Staining
The TMA slides were dewaxed and washed. Prior to immunohistochemical staining,
a citrate buffer with pH 6 (Dako EnVision Flex Target Retrieval Solution low pH; DM829;
lot 20048823, Agilent Technologies, Santa Clara, CA, USA) was used for heat-induced
epitope retrieval. Staining was performed by using an automated staining system (DAKO
Autostainerplus) and Envision Flex Kit (Dako EnVision TM FLEX HRP/Dab; K 8010),
according to manufacturers’ instructions. The following antibodies were used: p4EBP1
(T37/46) (Cell Signaling Technology, Danvers, MA, USA, #2855), pp70S6K (T389) (Cell
Signaling Technology, #9206), pS6 (S235/236) (Cell Signaling Technology, #4858), pPRAS
(T246) (Cell Signaling Technology, #2997), pmTOR (Cell Signaling Technology, #2976),
panAKT (Cell Signaling Technology, #4691), S6K1 (Abcam, Cambridge, UK, # ab32359); all
incubated for 30 min and mTOR (Cell Signaling Technology, #2983), and pAKT (S473) (Dako,
#S473); both were incubated for 60 min. An avidin-biotin-complex peroxidase technique,
using aminoethylcarbazole for visualization and hematoxylin for counterstaining, was
applied. Positive and negative controls were performed. pRaptor (Ser792) (Cell Signaling
Technology, #2083) was very weakly expressed in the PeCa tissue and therefore was
excluded from further analysis.
2.3. p16INK4a Staining
Prior to immunohistochemical staining of p16 EDTA, buffer pH 9 (Dako EnVision
Flex Target Retrieval Solution high pH; K 8004; lot 20062462) was used for heat-induced
epitope retrieval. Staining was performed by using an automated staining system (DAKO
Autostainerplus) and Envision Flex Kit (Dako EnVision TM FLEX HRP/Dab; K 8010)
according to manufacturers’ instructions. The following antibodies were used: p16 CINtec
Histology Kit (Roche, Basel, Switzerland, #E6H4) for 30 min. An avidin-biotin-complex
peroxidase technique, using aminoethylcarbazole for visualization and hematoxylin for
counterstaining, was used.
2.4. Staining Evaluation
The immunohistochemical semi-quantitative assessment of tumor markers expression
was determined by the staining intensity and quantity of immunoreactive tumor cells. The
intensity score was graded as 0 (negative), 1 (low), 2 (medium) and 3 (high) (Figure 1A–D).




Figure 1. Immunohistochemical PeCa tissue sections stained with AKT antibody representing in-
tensity score grades in 0 (A), 1 (B), 2 (C) and 3 (D), scale bar = 100 µm. p16INK4a staining was 
graded in negative (E) and positive (F). 
The quantity score (percentage of positive cells) ranged from 0 (negative), 1 (positiv-
ity in <25%), 2 (positivity in <50%) to 3 (positivity in >50%). The final immunoreactive 
score (IRS) was calculated by the product of staining intensity and quantity scores, rang-
ing from 0 to 9 [15]. The optimal cut-off values of IRS for discrimination between the 
groups with a “low” and “high” marker expression were determined with the Youden 
Index calculated on a receiver operating characteristic (ROC) curve based on patient sur-
vival data (Table S1) [16]. 
The immunohistochemical assessment of p16INK4a expression was classified as nega-
tive or positive (Figure 1E,F, respectively). 
2.5. HPV DNA Detection 
The total DNA was extracted from formalin-fixed and paraffin-embedded PeCa sam-
ples, using the standard kit (RSC DNA FFPE PLUS Custom Kit AX 4920, Promega, Mad-
ison, WI, USA) according to the manufacturers’ instructions. The presence of high-risk 
HPV was detected by PCT-based Sanger sequencing (CEQ 8000, Beckman Coulter, Brea, 
CA, USA), using the following primers and probes: Human Papilloma Virus E2 Gen: Pri-
mer 4XF, sequence 5′-GTAACACTACGCCTATAATACA-3′, Primer: 184559R, sequence 
5′-CCTGTCCAATGCCAGGT-3′; Human Papilloma Virus E1 Gen: Primer 311635F, se-
quence 5′-ATAGSYATGTTAGATGATGCTACA-3′, Primer: 6Pack-R, sequence 5′-CAC-
GTCCTTGAGAAAAAGGAT-3′; Major Capsid Protein L1-Region: Primer: MY11, se-
quence 5′-GCMCAGGGWCATAAYAATGG-3′, 5′-CGTCCMARRGGAWACTGATC-3′, 
Primer: MY09 sequence 5′-GATCAGTWTCCYYTKGGACG-3′. Genome Lab (GeXP Ge-
netic Analysis System, Beckman Coulter, Brea, CA, USA) was used for interpretation. 
2.6. Cell Culture 
Human penile cancer cell lines UKF-PeC-3 and UKF-PeC-4 were established from 
patients with PeCa as described previously [17,18]. In brief, samples of diagnosed PeCa 
tissue were cut into small pieces and treated twice with trypsin (0.2%) for 30 min. Trypsin 
was inactivated by 10% FBS and cells were seeded in EpiMedium (ScienCell) until cell 
adhesion. The media were changed at five day intervals. The UKF-PeC-3 cell line was 
derived from a tumor with a pT3 pN0 L0 G2 R0 histopathological PeCa and was positive 
for HPV DNA subtype 16. UKF-PeC-4 was isolated from a tumor with pT2 pN1 (1/27) L0 
V0 PN0 G2 R0 histopathological PeCa and was negative for hrHPV DNA. UKF-PeC-3 cells 
were cultured in IMDM supplemented with 10% FCS, 1% glutamax (Gibco, Thermo Fisher 
Scientific, Darmstadt, Germany), and 1% Anti/Anti (Gibco, Thermo Fisher Scientific, 
Darmstadt, Germany). UKF-PeC4 was grown in Epithelial Cell Medium (ScienCell Re-
Figure 1. Immunohistochemical PeCa tissue sections stained with AKT antibody representing
intensity score grades in 0 (A), 1 (B), 2 (C) and 3 (D), scale bar = 100 µm. p16INK4a staining was
graded in negative (E) and positive (F).
The quantity score (percentage of positive cells) ranged from 0 (negative), 1 (positivity
in <25%), 2 (positivity in <50%) to 3 (positivity in >50%). The final immunoreactive score
(IRS) was calculated by the product of staining intensity and quantity scores, ranging
from 0 to 9 [15]. The optimal cut-off values of IRS for discrimination between the groups
with a “low” and “high” marker expression were determined with the Youden Index
calculated on a receiver operating characteristic (ROC) curve based on patient survival
data (Table S1) [16].
The i unohistoche ical assess ent f I K4a expre sion was cla sified as nega-
tive or positive (Figure 1E,F, i l .
2.5. HPV DNA Detection
The total DNA was extracted from formalin-fixed and paraffin-embedded PeCa sam-
ples, sing the stan ar kit (RSC DNA FFPE PLUS Custom Kit AX 4920, Promega, Madison,
WI, USA) according to the manufacturers’ instructions. The presence of high-risk HPV
was detected by PCT-based Sanger sequencing (CEQ 8000, Beckman Coulter, Brea, CA,
USA), using the following primers and probes: Human Papilloma Virus E2 Gen: Primer
4XF, sequence 5′-GTAACACTACGCCTATAATACA-3′, Primer: 184559R, sequence 5′-
CCTGTCCAATGCCAGGT-3′; Human Papilloma Virus E1 Gen: Primer 311635F, sequence
5′-ATAGSYATGTTAGATGATGCTACA-3′, Primer: 6Pack-R, sequence 5′-CACGTCCTTGA
GAAAAAGGAT-3′; Major Capsid Protein L1-Region: Primer: MY11, sequence 5′-GCMCAG
GGWCATAAYAATGG-3′, 5′-CGTCCMARRGGAWACTGATC-3′, Primer: MY09 sequence
5′-GATCAGTWTCCYYTKGGACG-3′. Genome Lab (GeXP Genetic Analysis System, Beck-
man Coulter, Brea, CA, USA) was used for interpretation.
2.6. Cell Culture
Human penile cancer cell lines UKF-PeC-3 and UKF-PeC-4 were established from
patients with PeCa as described previously [17,18]. In brief, samples of diagnosed PeCa
tissue were cut into small pieces and treated twice with trypsin (0.2%) for 30 min. Trypsin
was inactivated by 10% FBS and cells were seeded in EpiMedium (ScienCell) until cell
adhesion. The media were changed at five day intervals. The UKF-PeC-3 cell line was
derived from a tumor with a pT3 pN0 L0 G2 R0 histopathological PeCa and was positive
for HPV DNA subtype 16. UKF-PeC-4 was isolated from a tumor with pT2 pN1 (1/27) L0
V0 PN0 G2 R0 histopathological PeCa and was negative for hrHPV DNA. UKF-PeC-3 cells
were cultured in IMDM supplemented with 10% FCS, 1% glutamax (Gibco, Thermo Fisher
Scientific, Darmstadt, Germany), and 1% Anti/Anti (Gibco, Thermo Fisher Scientific, Darm-
stadt, Germany). UKF-PeC4 was grown in Epithelial Cell Medium (ScienCell Research
Laboratories, Carlsbad) according to the manufacture’s manual at 37 ◦C in a humidified
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atmosphere with 5% CO2. Mycoplasma contamination was routinely examined. Cell
viability was assessed by Trypan blue staining (Gibco/Invitrogen, Darmstadt, Germany).
Cell lines were authenticated and validated (2021) using the primary tumor tissue by means
of STR (Short Tandem Repeats) profiling (Institute of Legal Medicine, Goethe-University
Frankfurt, Frankfurt, Germany).
2.7. Therapeutic Agent
The AKT inhibitor, capivasertib (AZD5363, AstraZeneca, UK), was used for in vitro
studies. This compound is a novel synthetic AKT inhibitor that is orally bioavailable
and was previously used in clinical trials [19,20]. For in vitro studies, capivasertib was
dissolved in dimethyl sulfoxide (DMSO) at 10 mmol/L stock solution and stored at−20 ◦C.
2.8. Measurement of Cell Viability
Cell viability was tested by using the 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium
bromide (MTT) dye. UKF-PeC-3 and UKF-PeC-4 cells were seeded into 96-well tissue
culture plate and treated with capivasertib at concentrations ranging between 0.3125 and
80 µg/mL. After 24, 48 and 72 h incubation at 37 ◦C in an atmosphere containing 5%
CO2, MTT (0.5 mg/mL) was added for 4 h. Subsequently, cells were lysed in a buffer
(10% SDS in 0.01 M HCl) and the plates were incubated overnight at 37 ◦C with 5% CO2.
Absorbance was detected at 570 nm by a multimode microplate-reader (Tecan, Spark 10 M,
Crailsheim, Germany). To demonstrate dose–response kinetics, the mean cell number after
24 h incubation was set to 100%. Each experiment was done in triplicate.
2.9. Chemotatic Activity of PeCa Cell Lines
Serum-induced chemotactic activity was investigated using 24-well Transwell cham-
bers with inserts (Corning, Glendale, Arizona, USA). UKF-PeC-3 and UKF-PeC-4 cell
lines, pre-stained with CellTracker Green CMFDA (Thermo Fisher Scientific, Darmstadt,
Germany), were incubated in the absence or the presence of 20 mol/L capivasertib for 72 h.
PeCa tumor cells (6 × 105/mL) were placed in the inserts (Corning, Glendale, AZ, USA) in
a cell culture medium containing 10% serum. The lower chamber contained cell culture
medium with 30% serum (Gibco, Thermo Fisher Scientific, Darmstadt, Germany). After
incubation of 24 h at 37 ◦C, the lower surface and insert of the Transwell membrane were
washed and gently wiped with a cotton swab to remove not migrated cells. Cells that had
migrated to the lower surface of the membrane were assessed and counted by Sapphire
Biomolecular Imager (Azure Biosystems, Inc., Dublin, CA, USA). Each experiment was
done in triplicate.
2.10. Western Blot
To validate the expression blockade of AKT and pAKT under capivasertib treatment,
a Western blot analysis was performed. PeCa cell lines were incubated in the absence
or the presence of 20 mol/L capivasertib for 72 h. Tumor cell lysates (50 µg; protein
concentration was quantified by BCA assay) were loaded onto a 7% polyacrylamide gel
and were electrophoresed for 10 min at 80 V and for 60–90 min at 120 V. The proteins
were then transferred to nitrocellulose membranes for 1 h at 100 V. After blocking with
non-fat dry milk for 1 h, the membranes were incubated overnight at 4 ◦C with monoclonal
antibodies directed against AKT (clone 55/PKBa/Akt, mouse immunoglobulin IgG1,
dilution 1:1000, Becton Dickinson, Franklin Lakes, NJ, USA) and pAKT ((Ser473) (D9E);
rabbit immunoglobulin IgG1; dilution 1:500; Cell Signaling Technology, Danvers, MA,
USA). Horseradish peroxidase-conjugated goat-anti-mouse IgG (AKT) and goat-anti-rabbit
IgG (pAKT) (IgG, both: dilution 1:1000, Dako, Glosturp, Denmark) served as the secondary
antibody (30 min incubation at room temperature).
The membranes were shortly incubated with ECL detection reagent (AC2204, Azure
Biosystems, Munich, Germany). Proteins were then visualized with a Sapphire Imager
(Azure Biosystems, Munich, Germany). Coomassie staining served as an internal loading
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control. The ratio of protein intensity/whole protein intensity was calculated and expressed
in percentage, related to untreated controls, set to 100%.
2.11. Statistical Analysis
Data were analyzed using the R software package (www.rproject.org; Version
3.6.0, accessed on 24 April 2021) and R Studio (Version 1.2.1335; www.rstudio.com,
last access on 24 April 2021). For the count data, Fisher’s exact test (two-sided) was
used. The Kaplan–Meier method was applied to calculate survival rates (overall (OS),
recurrence-free (RFS), disease-specific (DSS) and metastasis-free survival (MFS)). Uni-
variate survival data were tested for significance using the Mantel–Haenszel log-rank
test. For multivariate analysis, the Cox proportional hazards regression model was
used. Time-to-event variables were defined as the following: OS—time from the surgical
resection to death due to any cause; DSS—time from the surgical resection to death
caused by disease; RFS—time from the surgical resection to disease recurrence (local,
regional or distant) or death from any cause; MFS—time from the surgical resection to
first metastasis (regional or distant). Only metachronous events for recurrence or metas-
tasis, defined as those occurring at least 3 months after surgery of the primary tumor,
were included in MFS and RFS calculations. Correlation between the two parameters
was evaluated by the analysis of Spearman’s coefficient.
All in vitro experiments were performed at least three times. Statistical significance
was calculated with GraphPad Prism 7.0 (GraphPad Software Inc., San Diego, CA, USA):
two-sided t-test (Western blot and chemotaxis) and two-way ANOVA test (MTT). Cor-
rection for multiple comparisons was done using the conservative Bonferroni method.
Differences were considered statistically significant at a p-value ≤ 0.05.
3. Results
3.1. Clinicopathological Data
Between 1980 and 2018, we identified a total of 76 males with a cM0 PeCa with tissue
from invasive primary tumors suitable for analysis (Table 1). The median age was 67 years
(interquartile range, 31–86 years). Eight patients (10.5%) underwent circumcision, 3 pa-
tients (3.9%) underwent wide local tumor excision, 44 patients (57.9%) underwent partial
penectomy and 21 patients (27.6%) underwent total penectomy as a primary treatment.
Seventeen patients (22.4%) had high-grade primary tumors, 18 patients (23.7%) presented
with a locally advanced disease and 14 patients (18.4%) had node-positive disease (pN1-3).
Presence of a high-risk (hr)HPV was detected in 18 cases (23.7%; 16× HPV 16 and 2×
HPV 59). p16INK4a status was positive in 38 patients (50.0%). Overall, 18 tumors qualified
as HPV-induced (concomitant HPV+/p16INK4a+ status). p16INK4a immunopositivity was
significantly associated with presence of HR-HPV DNA (p < 0.001; Fisher’s exact test). In
total, the sensitivity of p16INK4a staining for the presence of HR-HPV was 90% (specificity
62.26%, positive predictive value (PPV) 47.37%, negative predictive value (NPV) 94.29%).
Table 1. Clinical baseline characteristics of the study population.
Clinical Characteristics Overall (n = 76)
Age at diagnosis
Mean (SD) 64.1 (11.9)





Tumor excision 3 (3.9%)
Partial penectomy 44 (57.9%)
Total penectomy 21 (27.6%)
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Table 1. Cont.
Clinical Characteristics Overall (n = 76)
Primary tumor grade
Low (G1/G2) 59 (77.6%)










































3.2. Tumor Marker Expression and Associations
AKT expression was increased in 10 patients (13.2%; Table S2; representative image of
different IRS scores—Figure 1), whereas its higher levels were significantly more prevalent
in high-grade tumors (Figure S1). In contrast, it was independent of pT-stage, age at
diagnosis, presence of lymph node metastasis or HPV infection.
Expression of pmTOR was elevated in 21 patients (27.6%; Table 2), while its higher
values were less common in high-grade primary tumors (p = 0.029; Figure S1). Moreover,
there was no impact of the primary pT-stage, age at diagnosis, presence of lymph node
metastasis or HPV infection on the pmTOR expression. There were no significant associ-
ations between the level of expression of pmTOR or its unphosphorylated form mTOR
with clinicopathological parameters (in particular, obesity and diabetes) in the univariate
analysis (Figure S2).
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Table 2. Multivariate COX regression analysis of survival endpoints.
Characteristic
OS DSS RFS MFS








Negative 1.00 (reference) 1.00 (reference)
Positive 36 (3.33–391) 0.003 11.97 (2.70–53.12) 0.001
Primary tumor
pT1 1.00 (reference)
pT2/pT3 0.318 (0.09–1.16) 0.0837
Diabetes
Negative 1.00 (reference)
Positive 3.86 (1.07–13.86) 0.0384
HTN
Negative 1.00 (reference)
Positive 0.337 (0.09–1.23) 0.0987
COPD
Negative 1.00 (reference)
Positive 2.86 (0.73–11.27) 0.133
Phimose
Negative 1.00 (reference)
Positive 0.246 (0.07–0.89) 0.0333
TNM N stage
Negative 1.00 (reference)
Positive 0.287 (0.05–1.67) 0.164
Grading
G1/G2 0.43 (0.16–1.18) 0.102
G3/G4 1.00 (reference)
AKT
Low expression 1.00 (reference) 1.00 (reference)
High expression 3.43 (1.22–9.68) 0.0197 7.53 (1.12–50.5) 0.0377
pmTOR
Low expression 1.00 (reference)
High expression 9.95 (1.25–79.3) 0.0301
p4epb1
Low expression 1.00 (reference)
High expression 5.99 (0.779–46.1) 0.0855
pPRAS
Low expression 1.00 (reference)
High expression 0.132 (0.01–1.62) 0.113
Expression levels of mTOR, pAKT, pS6, p4EBP1, pp70S6K, s6k1 and pPRAS are de-
picted in Table S2. There were no significant associations between the level of expression
of these proteins with clinicopathological parameters in the univariate analysis (Table S3).
Moreover, positivity for hrHPV DNA was not associated with clinicopathological charac-
teristics, prognosis and expression of marker candidates.
Expression levels of mTOR as well as that of AKT did not correlate with that of
its respective phosphorylated form pmTOR and pAKT. There was a respective positive
association between the expression of s6k1 and AKT (p = 0.002), p4EBP1 (p = 0.001), and
pS6 (p < 0.001). In addition, the expression of pS6 was respectively associated with pmTOR
(p = 0.001), pp70S6K (p = 0.003) and p4EBP1 (p = 0.001) expression (Figure 2).
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3.3. Follow-Up and Survival
During the median follow-up of 34.1 months for the total cohort, twenty-three patients
(30.3%) died, including eight cancer-specific deaths (10.5 ). In total, 18 patients (23.7%)
developed recurrent disease co prising 8 patients (10.5%) with local recurrence, one
patient (1.3%) with regional recurrence and 9 patients (11.8%) with distant recurrence.
Median time to lymphatic recurrence after first surgical treatment was 7.6 months. Eleven
patients (14.5%) were subjected to adjuvant chemotherapy. Five patients (6.6%) received
palliative therapy, of which two patients (2.6%) were treated with chemotherapy alone,
two patients with chemoradiotherapy and one patient (2.6%) received palliative radiation.
In the univariate COX regression analysis, lymph node metastasis was associated with
a shortened DSS (95% confidence interval [CI], HR 28.12 (3.39–232.94; p = 0.002) (Figure S3).
The univariate COX regression did not show statistically significant associations of clinical
parameters with OS and RFS.
Upon Kaplan–Meier analysis, higher expression of AKT was associated with worse
DSS and OS and a trend for inferior MFS as compared to the lower expression (p = 0.045,
p = 0.007 and 0.061, respectively), while there was no difference in RFS between both
groups (Figure 3).
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Figure 3. Kaplan–Meier plots of DSS (A), OS (B), RFS (C) and FS (D) according to AKT. igh expression of KT as
associated with a worse OS and DSS (p = 0.045 and p = 0.0066).
In addition, higher levels of p4EBP1were significantly associate ith an inferior DSS
(p = 0.034), while there were no di ferences in OS and RFS (Figure 4). A ditionally, a trend
for unfavorable MFS a sociated with higher expression of p4EBP1 was observed (p = 0.06).
Upon Kaplan–Meier analysis, expression of pmTOR was not associated with OS, RFS
and MFS, while a trend was observed for DSS (p = 0.064) (Figure S4).
In the multivariate COX regression analysis (Table 2), higher expression of AKT was
an independent predictor of worse OS (HR 3.43; 95% CI, 1.22–9.68; p = 0.02) and DSS (HR
7.53; 95% CI, 1.12–50.5; p = 0.038). In addition, an increased expression of pmTOR (HR 9.95;
95% CI, 1.25–79.3; p = 0.03) was an independent predictor of worse DSS.
Regarding clinicopathological parameters, correlation of lymph node metastasis with
inferior DSS and MFS was confirmed in the multivariate analysis (HR 36; 95% CI, 3.33–391;
p = 0.003, HR 11.97; 95% CI, 2.70–53.5.12; p = 0.001, respectively) (Table 2). In addition,
diabetes was an independent predictor of the worse (hazard ratio (HR) 3.86; 95% confidence
interval (CI), 1.07–13.86; p = 0.038) as well as the presence of phimosis (hazard ratio (HR)
0.246; 95% confidence interval (CI), 0.07–0.89; p = 0.033) of the more favorable RFS.
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3.4. Impact of AKT Blockade on Tumor Cell Growth
In bot PeCa cell lines, successful blocking of AKT and pAKT protein expression by
capivas rtib was verified by Western blot analysis (Figure 5A,B and Figures S5 and S6).
In order to evaluate he possibl effect of the AKT blockade on the functional behavior
of PeCa cells, the established cell lines UKF-PeC-3 und UKF-PeC-4 were exposed to the
pan-AKT inhibitor ca ivasertib in the rang of 0.3125 to 80 µg/mL. A dose- and time-
dependent growth inhibition was de onstrated in both cell lines, co p red to their
r spective u treated contr ls (Figure 5C,D). The effect w s hereby slightly stronger in
UKF-PeCa-4 cells since a significant growth inhibition was first reached with 10 µg/mL
(vs. 20 µg/mL i UKF-P Ca-3) after 72 h. Thus, for subsequent motility studies on both
PeCa cell lines, a working concentration of 20 µg/mL capivasertib was used. No signs of
toxicity were shown by the trypan blue exclusion test.
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3.5. Modulation of Motil ty by ibition
A trend for sup res ion of taxis was observed in UKF-PeC-3 cells after 72 h
capivasertib 20 µg/mL treat ent (Figure 5E). At the same time, exposure to the compound
decreased chemotactic move ent by almost 50% in UKF-PeC-4 cells as compared to the
untreated controls (Figure 5F).
4. Discussion
Extensive molecular characterization resulting in effective targeted therapy concepts
has recently sounded the bell for precision medicine in a number of malignancies. Unfortu-
nately, the advent of personalized treatment in PeCa as a rare disease is still neglectable,
not least because of a limited funding and inadequate interest of stakeholders in preclinical
research on the one hand and the scarcity of tumor models precluding molecular evidence-
based clinical trials n the other hand [21]. In this context, the PI3K/mTOR/AKT pathway,
a paramount sign ling network ste ring various physiologic ce lular processes, might
offer new approach s for targeted th rapy of PeCa. Importantly, a r cent genomic study
in PeCa revealed somatic missense mutations in the PIK3CA gene to be present in 9%,
and they convey the protein with more activity, thus stimulating the PI3K/mTOR/AKT
pathway [22]. Of note, different elements of this pathway were found to be activated
in human cancers [23]. Consequently, its blockade has been successfully evaluated in
preclinical and clinical oncologic settings at different levels, demonstrating an induction
of tumor regression and survival advantage [23]. During the last decade, a number of
inhibitors of this pathway have been approved for clinical application by the U.S. Food
and Drug Administration (FDA) [24]. In PeCa, molecular rationale for targeting members
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of this pathway is still vague, necessitating further preclinical data prior to its possible
transfer from lab to life.
Recently, Azizi and co-workers demonstrated that males with PeCa and a low expres-
sion of pAKT were at a higher risk of disease recurrence and those with a low expression
of its downstream protein pS6 had an increased mortality risk in their TMA study with
57 samples [25]. Moreover, high expression of pAKT was associated with low-grade
disease. Importantly, in our analysis, neither pAKT nor pS6 were associated with clinico-
pathological parameters or survival. Methodological issues of both differentially utilized
immunohistochemical scoring methods (H-score vs. IRS) and defined cut-off values (quar-
tile method vs. Youden index) for the classification of the low vs. high level of marker
expression might have contributed to the discrepancy between these two investigations.
Interestingly, in another TMA project on 112 invasive PeCa, Chaux et al. reported higher
pAKT expression in high-grade PeCa, in contrast to the data of Azizi et al. [26]. It is
noteworthy, however, that we observed more frequently increased values of total AKT
in high-grade disease, while its enhanced expression was independently predictive of
a poor OS and DSS, pointing to the involvement of the PI3K/mTOR/AKT pathway in
tumor cell survival and disease progression. Interestingly, a contemporary investigation
of 90 samples of oral squamous cell carcinoma revealed an upregulation of total AKT but
not pAKT in metastatic and non-metastatic tumor patients as compared to controls [27].
Remarkably, Javle and collaborators revealed an independent predictive ability of AKT for
OS as opposed to pAKT in cholangiocarcinoma, even if association between the expression
of AKT and pAKT was noticed [28]. In our study, there was no correlation between the
expression of both parameters, suggesting a presumably differential potential for testing as
a tumor marker beyond statistical issues. Inverse to our results, enhanced expression of
AKT correlated with improved survival in that assessment.
Interestingly, unlike OS, DSS and MFS (trend), the expression of AKT was not as-
sociated with RFS in the present study. This may be attributable to the fact that the
given time-to-event variable RFS includes local recurrences besides regional and distant
metastases, whereas local recurrence has presumably no negative impact on overall and
metastasis-free survival in PeCa [29]. Notably, the direction of the association between
AKT or pAKT expression and prognosis appears to vary depending on the malignancy.
For instance, a correlation between AKT activation and poor prognosis was shown for
prostate cancer and malignant melanoma [30,31]. At the same time, conflicting evidence
exists for non-small cell lung cancer (NSCLC). Thus, Lu and colleagues provided evidence
for the overexpression of pAKT being associated with metastasis and poor prognosis by
processing 341 NSCLC samples [32]. On the contrary, Shah and co-workers reported on
pAKT as a favorable prognostic factor despite being associated with a high tumor grade
in the analysis of 82 NSCLC specimens [33]. Importantly, AKT1 overexpression and gene
amplification were demonstrated to provide cisplatin resistance in lung cancer cells [34].
Suppression of AKT1 successfully rendered the cells sensitive for cisplatin in that study. In
another analysis, treatment of colon cancer cells with cisplatin induced significant elevation
of AKT, emphasizing its role in the development of chemoresistance in cancers [35].
Given the strongest association of the total AKT expression out of all investigated
candidates with poor features of PeCa in the current analysis and evidence for its crucial
role in adverse tumor behavior for other human cancers, we tested the potential of AKT
inhibition to exert antitumor properties in our two primarily established PeCa cell lines
UKF-PeC-3 and UKF-PeC-4. Treatment with the pan-AKT inhibitor capivasertib induced a
significant downregulation of both total AKT and pAKT, associated with decreased cell
viability. Concurrently, significantly reduced chemotaxis was demonstrated for UKF-PeC-4.
Capivasertib was previously shown to inhibit all three isoforms of AKT (AKT1, AKT2 and
AKT3) in enzyme assays and reduce phosphorylation of its downstream substrates P70S6K
or PRAS40 and in vitro growth of a subset of various cancer cell lines and xenografts [36,37].
Even if a correlation between capivasertib sensitivity and the presence of activating PIK3CA
mutations, PTEN loss or inactivating mutation, or HER2 amplification was observed, sev-
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eral cell lines without these aberrations turned out to be highly sensitive to this agent [36].
Of note, enhanced phosphorylation of AKT was demonstrated by the treatment of breast
and prostate cancer cell lines with capivasertib as a consequence of the protein being held
in a hyperphosphorylated but catalytically inactive form following compound binding [36].
It is noteworthy that in that study, cells were exposed to the drug for a period of 2 h.
Therefore, the observed upregulation of pAKT obviously depicts a short-term feedback
mechanism of counteracting its functional inhibition. In the investigation presented here,
treatment of cells with the compound lasted for 72 h, inducing sustainable suppression or
degradation of both AKT and pAKT.
In concert with the findings of other researchers, no association of the examined
mTOR/AKT pathway elements with the presence of hrHPV infection was detected [26,38].
Interestingly, the extent of the reduction of cell viability by capivasertib in our assessment
was comparable between the cell line generated from the hrHPV positive patient (UKF-
PeC-3) compared to that of the hrHPV negative patient (UKF-PeC-4). This observation
might point to the therapeutic potential of AKT inhibitors to effectively combat not only
HPV-dependent cancers with a well-described activation of the PI3K/AKT/mTOR pathway,
but also HPV negative ones, and is hypothesis-generating for the future evaluation [39].
Most recently, the efficacy of capivasertib was assessed in the nonrandomized phase 2
trial entitled NCI-MATCH, which enrolled patients with AKT1 E17K-mutated metastatic
tumors of different origin that either had progressed after at least one line of standard
systemic treatment or for which no effective therapy exists [40]. This aberration increases
activity of AKT signaling by promoting localization of AKT to the plasma membrane
through a PI3K-independent mechanism [41]. In these pretreated malignancies, the overall
response rate was 28.6% and 6-month progression-free survival of 50%, but treatment
was discontinued due to toxic side effects in 31% of participants, thus yielding a tolerable
safety profile. In addition, a double-blind phase 2 trial called PAKT randomized women
with metastatic triple negative breast cancer to receive paclitaxel with or without capi-
vasertib [42]. In the overall population, the risk of death was decreased by 39%, whereas
in the subset of females with PIK3CA/AKT1/PTEN-altered tumors, it was reduced by
70%, using combination treatment as compared to paclitaxel monotherapy. The rate of
grade 3/4 adverse events in the combination arm was 54.4%. These encouraging data,
corroborated by our in vitro analysis, pave the way to test the concept of AKT inhibition
in PeCa as a mono or combination therapy. In particular, taking into account the role of
AKT in cisplatin resistance in different cancers as well as the observed sensitization of
cisplatin-sensitive and -resistant ovarian cancer cells by adding capivasertib, combining
AKT inhibitors with cisplatin as the hub of the systemic therapy for metastasized PeCa
presents an intriguing novel therapeutic option [34,35,43]. Whether the presence of acti-
vating genomic alterations of the PIK3CA/AKT1/PTEN pathway represents a clinically
relevant predictive factor for selecting PeCa patients for AKT inhibition has to be further
elucidated. From the clinical point of view, several indications for the use of AKT inhibitors
merit future scientific efforts in PeCa. Successful generation of our cell lines paves the
way for the establishment of chemotherapy- and other drug-resistant sublines in which
molecular concepts of overcoming resistance, including AKT blockade, can be assessed,
aiming at identification of efficacious second-line treatment options after failure of the pri-
mary systemic treatment. Moreover, utilization of AKT inhibitors in neoadjuvant, adjuvant,
topical cytoreductive or, in case of superficial lesions, curative indications is an appealing
area of ongoing translational research.
Previously, Ferrandiz-Puildo and co-authors reported the overexpression of pmTOR
to be associated with lymph node-positive disease and higher pT stages as well as that of
p4EBP1 with lower pT stages in their TMA study on 67 men with invasive PeCa [44]. Sur-
prisingly, in our investigation, augmented expression of pmTOR correlated with low-grade
PeCa and was, at the same time, predictive of unfavorable DSS. At first glance, this result
appears counterintuitive. However, higher tumor grade was not independently predictive
of survival in the current analysis. In concert with our findings, several other groups also
Cancers 2021, 13, 2323 15 of 18
reported no association between the tumor grade and cancer progression or prognosis in
PeCa [45–48]. Apart from a possible statistical bias related to the limited sample size of the
study cohort, one explanation might be that mTOR activation in low-grade PeCa could
accelerate translational activity and oxygen consumption as it was previously assumed for
prostate cancer [49]. During transition from well to poorly differentiated disease, evolving
hypoxia has the potential to suppress mTOR signaling, leading to the downregulation
of pmTOR in high-grade tumors [50]. While tumor grade has no impact on prognosis
in this investigation, the detrimental influence of mTOR activation on DSS turns out to
be apparent in the multivariate analysis. Since no evidence exists on this issue in PeCa,
research on hypoxia-associated aspects of this disease is warranted. In addition, it would
be intriguing to assess the value of mTORC1 and mTORC2 in PeCa since the current project
focused on total mTOR. Of note, association of the overexpression of pmTOR with mostly
adverse cancer features were reported in other squamous cell carcinomas as well [27,51].
As previously reported, mTOR regulates lipid and glucose metabolism, thus playing a
major role in metabolic diseases, such as obesity and diabetes mellitus type 2 [52]. Interest-
ingly, neither obesity nor diabetes were associated with higher or lower mTOR/pmTOR
expression in our studies.
In addition, increased content of p4EBP1 indicated a shorter DSS on the log-rank test,
while a trend was observed for this association in the multivariable model (p = 0.09) in
the current study. Since evidence on the potential value of this candidate to serve as a
tumor marker or therapeutic target is scant (not only in PeCa), further research in this area
is welcome.
Due to the rarity of the disease, the generalization of the findings of our study is
hampered by the sample size limiting the stability of the statistical models as well as
by the number of investigated cell lines. Additionally, since lymphovascular invasion
and, hence, classification of pT1 stage in pT1a and pT1b was first available after 2010,
limited information in these categories as observed in several other studies precluded their
robust incorporation in our statistical models [53,54]. Nonetheless, we hope to have put
a relevant piece to the scientific puzzle of the molecular background of PeCa, yielding
hypothesis-generating results, emboldening future scientific efforts.
5. Conclusions
A number of proteins of the mTOR/AKT signaling pathway demonstrate association
with the histological and survival parameters of patients with PSCC, and AKT appears to
be the most promising one. This is further corroborated by in vitro experiments.
Supplementary Materials: The following are available online at https://www.mdpi.com/article/10
.3390/cancers13102323/s1. Figure S1: Dichotomized biomarker expressions of AKT and pmTOR
correlated with clinical and histopathological data (grading, primary tumor, lymph node metastases,
HPV infection and age). The Fischer’s exact test was used for statistical analysis. High expression
of AKT (p = 0.044) and low expression of pmTOR (p = 0.029) were associated with high-grade
primary tumors. Figure S2: Expressions of mTOR and pmTOR correlated with clinical data (diabetes
and obesity). Y-axis: immunoreactive score (IRS). X-axis: yellow boxplots—low expression of the
respective biomarker, blue boxplots—high expression of the respective biomarker. Box (represents
the interquartile range (IQR)): lower line—quartile Q1 (25%-quantile); middle line—median; upper
line—quartile Q3 (75%-quantile); whisker—separate values lying outside the IQR; circles—outliers.
The Fischer’s exact test was used for statistical analysis. Figure S3: Univariate COX regression
analysis: lymph node metastasis was associated with a shortened disease-specific survival (DSS)
(p < 0.0001). Figure S4: Kaplan–Meier Plots of disease-specific survival (DSS) (A), overall survival (OS)
(B), recurrence-free survival (RFS) (C) and metastasis-free survival (MFS) (D) according to pmTOR.
Figure S5: Protein expression profile in UKF-PeC-3 and UKF-PeC-4 cells without/after treatment
with capivasertib. Protein expression of AKT (a), corresponding Coomassie blue staining of total
protein (b). Figure S6: Protein expression profile in UKF-PeC-3 and UKF-PeC-4 cells without/after
treatment with capivasertib. Protein expression of pAKT (a), corresponding Coomassie blue staining
of total protein (b). Table S1: Immunoreactive scores (IRS). IRS determined as cutoff levels (low
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and high) after graphically depicting the survival curves of each of the scores separately by receiver
operating characteristic (ROC). Table S2: Immunohistochemical staining results with a respective
group classification. Values in brackets: percentage from total number. Table S3: Clinicopathological
parameters stratified by expression of the assessed marker candidates.
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